CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: March-14-16
Credit Expiration Date: March-14-17


Serena Cardillo, MD
Associate Professor of Clinical Medicine
Division of Endocrinology, Diabetes & Metabolism
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA

NJAFP: Everett Schlam, MD
AANP: Frances Sahebzamani, PhD, ARNP, FAANP
AAPA: Eric Peterson, EdM, FACEHP, CHCP

Credit Hours

FPs: 0.75 AAFP Prescribed Credit
NPs: 0.75 Contact Hour of continuing education (which includes 0.75 hours of pharmacology)
PAs: 0.75 AAPA Category 1 CME Credit



Program Description

The management of type 2 diabetes mellitus (T2DM) remains a major clinical challenge as many patients continue to struggle with achieving therapeutic goals. The goal of this activity is to improve knowledge and competency among primary care clinicians with regard to addressing glycemic variability in patients with T2DM through optimal therapeutic management, with a particular focus on the optimal use of GLP-1 receptor agonists and DPP-4 inhibitors in individualized treatment regimens.

Program Developer/Facilitator

Developed by the New Jersey Academy of Family Physicians (NJAFP), the American Association of Nurse Practitioners (AANP), and the American Academy of PAs (AAPA) in cooperation with MCM Education.

Target Audience

This program was developed for family medicine and primary care physicians, PAs, and nurse practitioners.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Describe the actions and effects of incretin-based therapies on measures of glycemic control, including A1c levels and postprandial glucose targets.
  2. Review the effects of GLP-1 receptor agonists and DPP-4 inhibitors on cardiovascular risk factors, including lipid levels and blood pressure.
  3. Outline evidence associating GLP-1 receptor agonists and DPP-4 inhibitors with changes in body weight.


Serena Cardillo, MD, has no conflicts of interest to disclose.

Everett Schlam, MD , has no conflicts of interest to disclose.
Frances Sahebzamani, PhD, ARNP, FAANP, has no conflicts of interest to disclose.
Eric Peterson, EdM, FACEHP, CHCP, has no conflicts of interest to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Credit Statements

This Enduring Material activity, Treatment Patterns in Family Medicine: Clinical Perspectives on Incretin-Based Therapies in the Management of T2DM, has been reviewed and is acceptable for up to 0.75 Prescribed credit(s) by the American Academy of Family Physicians. Term of approval begins 03/14/2016. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners
This activity is approved for 0.75 contact hour of continuing education (which includes 0.75 hours of pharmacology) by the American Association of Nurse Practitioners. Program ID 16022106.

This program was planned in accordance with AANP CE Standards and Policies.

Physician Assistants
This program has been reviewed and is approved for a maximum of .75 AAPA Category 1 CME credits by the Physician Assistant Review Panel. Approval is valid for one year from the issue date of 03/14/2016. Participants may submit the self-assessment at any time during that period.

This program was planned in accordance with AAPA’s CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

Commercial Support Statements

This activity is supported by an independent educational grant from Novo Nordisk.


There are no fees for participating in or receiving credit for this online educational activity.

  1. Review the intended audience, learning objectives, and author disclosures.
  2. Study the educational content online. Be sure to review both written and audio/slide content. Note: For optimal viewing on mobile devices, please view horizontally.
  3. After reviewing the activity, click the "Post-Test" tab to select the type of credit you would like to receive. Then, continue to the post-activity survey and post-test. You will also be asked to complete an activity evaluation.

    To receive AANP CE Credit: At the end of this activity, you will receive the program’s access code to complete the posttest/evaluation for this activity and claim credit. In the AANP CE Center for this program, you will click Get Certificate and choose Participation Codes. Enter the code provided and the posttest/evaluation will be available to you.

    To receive AAPA Credit, you will be redirected to the AAPA website.

  4. Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers

Certificate Fee



The opinions expressed in this presentation are those of the speaker and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the New Jersey Academy of Family Physicians (NJAFP), the American Association of Nurse Practitioners (AANP), and the American Academy of PAs (AAPA), or Novo Nordisk. Any medications, diagnostic procedures, or treatments discussed by the activity presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu